SCHEMBL1948739

SCHEMBL1948739

O=C(c1ccccc1)N(Cl)C(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.66
CES2 O00748 1/20 0.66
CRHBP P24387 1/20 0.62
CRHR2 Q13324 1/20 0.62
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 1/20 0.56
POLB P06746 2/20 0.56
MAPK1 P28482 2/20 0.56
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
NPC1 O15118 1/20 0.53
MITF O75030 1/20 0.53
RAB9A P51151 1/20 0.53
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
SRD5A2 P31213 1/20 0.51
TSHR P16473 1/20 0.50
BCHE P06276 1/20 0.50
MAOB P27338 1/20 0.50
CYP1B1 Q16678 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1950874 0.93 ALDH1A1 (0.68) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL28723024 0.86 CES1 (0.66) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL9507468 0.84 CRHBP (0.64) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL12546534 0.82 CES1 (0.55) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL9849003 0.81 CES1 (0.50) CES1CES2ALDH1A1TDP1POLB
SCHEMBL27853418 0.80 POLB (0.77) CES1CES2ALDH1A1TDP1POLB
SCHEMBL29042306 0.80 ALDH1A1 (0.60) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL11135292 0.80 ALDH1A1 (0.62) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL11674649 0.80 CRHBP (0.59) CES1CES2CRHBPCRHR2ALDH1A1
SCHEMBL229627 0.80 POLB (0.82) CES1CES2ALDH1A1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018411-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-04-28 US claimed
US-9458127-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2016-10-04 US disclosed
US-20150197502-A1 Bis-Acylated Hydroxylamine Derivatives THE JOHNS HOPKINS UNIVERSITY 2015-07-16 US disclosed
US-9018411-B2 Bis-acylated hydroxylamine derivatives CARDIOXYL PHARMACEUTICALS, INC. (US) 2015-04-28 US disclosed
EP-2509942-A2 BIS-ACYLATED HYDROXYLAMINE DERIVATIVES Johns Hopkins University (US) 2012-10-17 EP disclosed
WO-2011071947-A2 BIS-ACYLATED HYDROXYLAMINE DERIVATIVES JOHNS HOPKINS UNIVERSITY (US) 2011-06-16 WO disclosed
US-20110136827-A1 Bis-Acylated Hydroxylamine Derivatives THE JOHNS HOPKINS UNIVERSITY 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197502-A1 Bis-Acylated Hydroxylamine Derivatives CPT1A, TNNI3, NOS2 CES1 526/4885CES2 758/4885CRHBP 4108/4885
US-20110136827-A1 Bis-Acylated Hydroxylamine Derivatives CPT1A, TNNI3, NOS2 CES1 526/4885CES2 758/4885CRHBP 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.